Article Text
Abstract
Introduction/Background In 2020, the European Society of Gynecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology (ESGO/ESTRO/ESP) integrated molecular classification into the classic risk stratification based on clinicopathological features of patients with endometrial cancer (EC), thus introducing a new decision-making for clinicians in adjuvant therapy. Therefore, each surgical specimen should be tested for mutations in the tumor protein 53 (p53), in mismatch repair (MMR) proteins and Polimerase Epsilon (POLE). However, this may be too expensive and not always necessary. Betella’s algorithm (figure 1) therefore pointed to test only for mutations that would actually change the risk group and consequently the adjuvant treatment: first of all, analysis of MMR proteins; then research for p53 mutation in stages I and II of disease according to International Federation of Gynecology and Obstetrics (FIGO) 2009; finally, the sequencing of POLE when class migration occurred. Currently, available data allow class migration ’only’ in stage I-II endometrial cancers, in FIGO grade 3 and when lymphovascular spaces are involved.
Methodology The study aimed to externally validate Betella’s algorithm by retrospective analysis of EC cases treated between March 2021 and March 2023 at the Gynecology Clinic of S. Maria della Misericordia Hospital in Udine, Italy.
Results Of 102 patients underwent surgical staging, complete molecular analysis was obtained in 97%. Integrating molecular classification in the calculation of risk groups resulted in a risk group move in 11.1% of patients: 7 moved to a lower risk group due to POLE mutations, while 4 shifted to a higher risk group due to p53 mutations. By applying the Betella algorithm, we were able to spare POLE sequencing in 65 cases (65.7%) and p53 immunohistochemistry in 17 cases (17.2%) (figure 2).
Conclusion The application of this proposed new algorithm appears safe for patients and allows rationalization of resources.
Disclosures Authors have no disclosures to declare.